Abstract
Background
This study serves as a follow-up to a March 2012 analysis conducted by Frank Sasinowski that reviewed the quantum of effectiveness evidence that is required to secure FDA approval of therapies for rare diseases, or orphan drugs, from the 1983 enactment of the Orphan Drug Act through June 30, 2010. The current study was designed to determine, over the 4 years since the original study, how frequently FDA has required marketing applications of drugs for rare diseases to provide the conventional level of proof of effectiveness that is ordinarily expected for most drugs for prevalent diseases.
Methods
This study employed methods similar to the original analysis, identifying the noncancer orphan drugs approved as new chemical entities by relying on FDA’s publicly available documents for drugs approved by FDA from July 1, 2010, to June 30, 2014. These materials were used to identify the basis for each drug’s approval, and each approval was analyzed and classified.
Results
The results of this study show that for just over two-thirds of all noncancer orphan drugs approved between July 1, 2010, and June 30, 2014, FDA did not require the orphan drug applications to provide the conventional level of proof of effectiveness that is ordinarily expected for drugs for prevalent diseases. This is consistent with the results of the 2012 analysis.
Conclusions
The findings further support that FDA has demonstrated extraordinarily reasonable flexibility in its review of certain applications for orphan drugs and reinforce the need for FDA and drug companies to better understand and discuss the various types of flexibility.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
21st century cures—patients. Washington, DC: House, Energy and Commerce Committee. http://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/analysis/21stCenturyCures/20140516PatientsWhitePaper.pdf. Accessed March 6, 2015.
Federal Food, Drug, and Cosmetic Act § 526(d), 21 USC 360bb(d) (1985).
Orphan Drug Act. Pub. L. No. 97-414, 96 Stat. 2049 (1983).
Federal Food, Drug, and Cosmetic Act § 505(d), 21 USC 355(d) (1962).
Sasinowski FJ. Quantum of effectiveness evidence in FDA’s approval of orphan drugs: cataloging FDA’s flexibility in regulating therapies for persons with rare disorders. Drug Information Journal. 2012;46(2):238–263. http://www.rarediseases.org/docs/policy/NORDstudyofFDAapprovaloforphandrugs.pdf. Accessed November 10, 2014.
Woodcock J. The future of orphan drug development. Nature. 2012;92(2):146–148.
National Human Genome Research Institute, National Institutes of Health. Frequently asked questions about rare diseases. http://www.genome.gov/27531963. Accessed November 24, 2014.
Federal Food, Drug, and Cosmetic Act § 505(d), 21 USC 9 (1962).
21 CFR § 314.126. Adequate and well-controlled studies. Fed Regist. 1985;50(51):7493–7507.
US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Rockville, MD: Center for Drug Evaluation and Research; 1998.
Food and Drug Administration Modernization Act of 1997 §115, 21 USC 355 (2014).
21 CFR Part 314, Subpart H—accelerated approval of new drugs for serious and life-threatening illnesses. Fed Regist. 1992;57(239):58942–58960.
Food and Drug Administration Safety and Innovation Act of 2012 § 901, 21 USC 356 (2012).
US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. Rockville, MD: Center for Drug Evaluation and Research; 2014.
Sasinowski F, Varond A. E-filing on Regulations.govURL. Hyman, Phelps & McNamara, P.C. re: Docket No. FDA-2013-D-0575, Comment on Section VII. C.: evidentiary criteria for accelerated approval of the FDA Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. http://www.regulations.gov/contentStreamer?objectId=09000064813ca6cb&disposition=attachment&contentType=pdf. Published August 26, 2013. Accessed November 10, 2014.
US House of Representatives, Energy & Commerce Committee. 21st century cures: incorporating the patient perspective [video]. http://energycommerce.house.gov/hearing/21st-century-cures-incorporating-patient-perspective. Accessed November 10, 2014.
Sasinowski FJ. Testimony—Committee on Energy and Commerce Subcommittee on Health, Tuesday, May 20, 2014, 21st Century Cures Initiative & Examining PCAST to Advance Developing Medicines for Americans. http://docs.house.gov/meetings/IF/IF14/20140520/102237/HHRG-113-IF14-Wstate-SasinowskiF-20140520.pdf. Accessed November 10, 2014.
Egan A. Center for Drug Evaluation and Research, US Food and Drug Administration: office director memo for Elosulfase alfa (vimizim) [decisional memo]. February 14, 2014.
Mulberg A. Drug development in rare and orphan diseases: efficacy endpoint and clinical outcome assessment considerations in registration trials [PowerPoint presentation]. Vimizim (elosulfase alfa) Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring, MD, November 19, 2013.
US Food and Drug Administration, Center for Drug Evaluation and Research. Medical review of glucarpidase (Voraxaze). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125327Orig1s000MedR.pdf. Published December 19, 2011. Accessed November 10, 2014.
Nguyen C. US Food and Drug Administration, Center for Drug Evaluation and Research: summary basis for regulatory action. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000SumR.pdf. Published December 21, 2012. Accessed November 10, 2014.
Juxtapid (lomitapide) label, NDA 203858, 26. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf. Published December 2012. Accessed November 10, 2014.
Golden J. US Food and Drug Administration, Center for Drug Evaluation and Research: medical review of Myalept (metreleptin for injection). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125390Orig1s000MedR.pdf. Published February 23, 2014. Accessed November 7, 2014.
Parks M. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for Myalept (metreleptin). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125390Orig1s000ODMemo.pdf. Published February 24, 2014. Accessed November 10, 2014.
US Food and Drug Administration, Center for Drug Evaluation and Research. Medical review of pasireotide diaspartate (Signifor). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000MedR.pdf. Published February 17, 2012. Accessed November 10, 2014.
US Food and Drug Administration, Center for Drug Evaluation and Research. Summary review for regulatory action of pasireotide diaspartate (Signifor). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125390Orig1s000SumR.pdf. Published February 17, 2012. Accessed November 10, 2014.
Rosebraugh C. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for pasireotide diaspartate (Signifor). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000ODMemo.pdf. Published December 14, 2012. Accessed November 10, 2014.
Cox E. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for bedaquiline (Sirturo). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000ODMemo.pdf. Published December 14, 2012. Accessed November 10, 2014.
21 CFR Part 314.600 and 21 CFR Part 601.90—approval of new drugs when human efficacy studies are not ethical or feasible. Fed Regist. 2002;67(105):37988–37998.
Epstein J. US Food and Drug Administration: approval letter to Cangene Corporation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm345137.htm. Published March 22, 2013. Accessed November 10, 2014.
US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology biopharmaceutics review of botulism antitoxin heptavalent (BAT). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-922_Solage_biopharmr.pdf. Published June 2, 1998. Accessed November 10, 2014.
Centruroides (scorpion) immune F(ab′)2 (equine) injection (Anascorp) label, 2. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm266725.pdf. Published July 2011. Accessed November 10, 2014.
Ko HS. US Food and Drug Administration, Center for Biologics Evaluation and Research: clinical review of centruroides (scorpion) immune F(ab′)2 (equine) injection (Anascorp). http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270159.pdf. Published May 6, 2011. Accessed November 10, 2014.
Vanco D. Medical review for coagulation factor XIII concentrate (human)—Corifact. August 18, 2010.
Pazdur R. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for deferiprone (Ferriprox). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ODMemo.pdf. Published October 14, 2011. Accessed November 10, 2011.
Unger E. US Food and Drug Administration, Center for Drug Evaluation and Research: summary review for droxidopa (Northera). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203202Orig1s000SumR.pdf. Published February 18, 2014. Accessed November 10, 2014.
Zhang J. US Food and Drug Administration, Center for Drug Evaluation and Research: statistical review for droxidopa (Northera). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203202Orig1s000StatR.pdf. Published August 12, 2013. Accessed November 10, 2014.
Beitz J. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for hydroxyprogesterone caproate (Makena). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021945Orig1s000ODMemo.pdf. Retrieved February 3, 2011. Accessed November 10, 2014.
Rosebraugh J. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for icatibant (Firazyr). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150Orig1s000ODMemo.pdf. Published August 25, 2011. Accessed November 10, 2014.
Opsumit (macitentan) label, NDA 204410, 11. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf. Published October 18, 2013. Accessed November 24, 2014.
Temple R. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for macitentan (Opsumit). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000ODMemo.pdf. Published October 19, 2012. Accessed November 10, 2014.
Farley J. US Food and Drug Administration, Center for Drug Evaluation and Research: deputy office director memo for miltefosine (Impavido). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000ODMemo.pdf. Published April 19, 2013. Accessed November 10, 2014.
Kynamro (mipomersen sodium), NDA 203568, 19. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203568s000lbl.pdf. Published January 19, 2013. Accessed November 14, 2014.
Nguyen C. US Food and Drug Administration, Center for Drug Evaluation and Research: deputy office director memo for mipomersen (Kynamro). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203568Orig1s000ODMemo.pdf. Published January 29, 2013. Accessed November 10, 2014.
Cox E. US Food and Drug Administration, Center for Drug Evaluation and Research: approval letter to Human Genome Sciences, Inc. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125349Orig1s000Approv.pdf. Published December 14, 2012. Accessed November 10, 2014.
Cox E. US Food and Drug Administration, Center for Drug Evaluation and Research: office director memo for raxibacumab. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125349Orig1s000ODMemo.pdf. Published December 14, 2012. Accessed November 10, 2014.
Taliglucerase alfa (Elelyso) label, NDA 22458, 4. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022458lbl.pdf. Published May 1 2012. Accessed November 10, 2014.
Vali B. Center for Drug Evaluation and Research: statistical review for taliglucerase alfa (Elelyso). Published February 24, 2011.
Beitz J. US Food and Drug Administration, Center for Drug Evaluation and Research: summary review for taliglucerase alfa (Elelyso). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022458Orig1s000SumR.pdf. Published May 1, 2012. Accessed November 10, 2014.
Vali B. US Food and Drug Administration, Center for Drug Evaluation and Research: statistical review for taliglucerase alfa (Elelyso). Published May 2, 2012.
Gattex (teduglutide [rDNA origin]) label, NDA 203441, 4. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203441Orig1s000lbl.pdf. Published December 21, 2012. Accessed November 24, 2014.
Vali B. US Food and Drug Administration, Center for Drug Evaluation and Research: statistical review for teduglutide (Gattex). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203441Orig1s000StatR.pdf. Published November 30, 2012. Accessed November 10, 2014.
Kusiak V. US Food and Drug Administration, Center for Drug Evaluation and Research: deputy office director memo for teduglutide (Gattex). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203441Orig1s000ODMemo.pdf. Published December 21, 2012. Accessed November 10, 2014.
President’s Council of Advisors on Science and Technology. Report to the president on propelling innovation in drug discovery, development, and evaluation. Washington, DC: Executive Office of the President, President’s Council of Advisors on Science and Technology. http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf. Published 2012. Accessed November 10, 2014.
US Food and Drug Administration. Report: complex issues in developing drugs and biological products for rare diseases and accelerating the development of therapies for pediatric rare diseases including strategic plan: accelerating the development of therapies for pediatric rare diseases. http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM404104.pdf. Published July 2014. Accessed November 10, 2014.
FDA Voice Blog. http://blogs.fda.gov/fdavoice/index.php/2014/05/fdas-final-guidance-on-expedited-drug-approvals-fueling-innovation-and-helping-patients/. Published May 29, 2014. Accessed November 10, 2014.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sasinowski, F.J., Panico, E.B. & Valentine, J.E. Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs: Update, July 2010 to June 2014. Ther Innov Regul Sci 49, 680–697 (2015). https://doi.org/10.1177/2168479015580383
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015580383